Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of CPL500036 in Healthy Volunteers
NCT03873324Phase 1Completed
- Sponsor
- Celon Pharma S.A.
- Start
- Dec 2018
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cpl500036 in schizophrenia and levodopa-induced dyskinesia (LID) (3 arms), sponsored by Celon Pharma S.A. Primary endpoints: Maximum Tolerated Dose at 24 hours and Safety and Tolerability at 28 days. Started Dec 2018; status: completed.
02
Drugs
cpl500036
03
Conditions
schizophrenialevodopa-induced dyskinesia (LID)
Beyond the preview
Go deeper on NCT03873324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03873324.